With a known history of MI, the ECG picture becomes much clearer and more reassuring. Here is the updated interpretation:
Updated ECG Interpretation - Known History of MI
What Changes With This History
The anteroseptal infarct pattern (QS/rS morphology in V1-V3) is now almost certainly an old, established finding rather than an acute event. This is the expected residual scar pattern following a prior anteroseptal MI.
Final Interpretation
| Finding | Significance |
|---|
| Sinus rhythm, 69 bpm | Normal - stable |
| PR 168 ms | High-normal, not pathological |
| RBBB (QRS 166 ms) | Likely chronic - may have developed at time of original MI or shortly after |
| QS pattern V1-V3 | Old anteroseptal infarct scar - expected with prior MI history |
| QTc 467 ms | Borderline - monitor medications |
| Normal axis | No additional hemiblock |
Pathophysiology Explained
The RBBB + anteroseptal infarct combination is a classic post-MI finding. The LAD (left anterior descending artery) supplies:
- The anterior and septal walls of the left ventricle (hence the Q waves in V1-V3)
- The right bundle branch (hence the RBBB)
A proximal LAD occlusion can damage both simultaneously, producing exactly this pattern - sometimes called "peri-infarct block", which is precisely what the machine flagged.
What to Look For on Follow-Up
Even with a known MI history, be alert to changes from baseline:
- New or worsening ST elevation - could signal re-infarction or LV aneurysm formation
- New T-wave changes - particularly in leads overlying the old infarct territory
- QTc trending up - if on antiarrhythmics, watch for drug-induced QT prolongation
- Symptoms - any chest pain, dyspnea, or syncope warrants serial troponins regardless of the chronic ECG appearance
Clinical Bottom Line
This ECG is consistent with stable, chronic post-MI changes. The RBBB is likely a permanent sequela of the original infarction. No acute ischemic changes are apparent. Routine cardiology follow-up and optimization of secondary prevention medications (aspirin, statin, ACE inhibitor/ARB, beta-blocker) remain the priority.
This is an educational interpretation only. Clinical decisions require physician assessment of the full clinical picture.